Pharvaris (PHVS) Research & Development (2020 - 2026)
Pharvaris (PHVS) posted Research & Development of -$35.3 million for Q1 2026, up 11.15% on a QoQ basis from -$39.7 million in Q4 2025, and down 8.59% year-over-year from -$38.6 million in Q1 2025.
Pharvaris (PHVS) Research & Development (2020 - 2026) Analysis & Trends
Pharvaris' Research & Development history runs 7 years deep, the most recent figure standing at -$35.3 million for Q1 2026.
- Quarterly Research & Development fell 8.59% year-over-year to -$35.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$76.4 million (down 10.18% YoY) and the FY2025 annual result came in at -$140.6 million, down 31.83% from the prior year.
- Research & Development was -$35.3 million for Q1 2026 at Pharvaris, up from -$39.7 million in the prior quarter.
- Across five years, Research & Development topped out at $121.1 million in Q4 2023 and bottomed at -$39.7 million in Q4 2025.
- A 5-year average of $1.3 million and a median of -$15.2 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development soared 250.83% — and 2024, when it sank 127.53%.
- Pharvaris' Research & Development stood at $100.7 million in 2022, then increased by 20.24% to $121.1 million in 2023, then slumped by 127.53% to -$33.3 million in 2024, then fell by 19.2% to -$39.7 million in 2025, then advanced by 11.15% to -$35.3 million in 2026.
- Business Quant data shows PHVS's Research & Development at -$35.3 million in Q1 2026, -$39.7 million in Q4 2025, and -$34.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Pharvaris | 2.17 Bn | 1.88 Bn | - | -35.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.31 Mn |
| Dec 31, 2025 | -39.74 Mn |
| Sep 30, 2025 | -34.86 Mn |
| Jun 30, 2025 | 33.51 Mn |
| Mar 31, 2025 | -32.52 Mn |
| Dec 31, 2024 | -33.34 Mn |
| Sep 30, 2024 | -28.32 Mn |
| Jun 30, 2024 | 24.84 Mn |
| Mar 31, 2024 | -20.11 Mn |
| Dec 31, 2023 | 121.08 Mn |
| Sep 30, 2023 | -20.18 Mn |
| Jun 30, 2023 | 15.99 Mn |
| Mar 31, 2023 | -14.75 Mn |
| Dec 31, 2022 | 100.70 Mn |
| Sep 30, 2022 | -14.21 Mn |
| Jun 30, 2022 | 14.64 Mn |
| Mar 31, 2022 | -15.17 Mn |
| Dec 31, 2021 | 28,700.24 Bn |
| Sep 30, 2021 | -10.56 Mn |
| Jun 30, 2021 | -9.71 Mn |